Earlier studies before large-scale ARV introduction had reported the emergence of resistance in individuals undergoing treatment in some African countries including C??te d'Ivoire, Uganda, South Africa, and Zimbabwe.3-7 Because of the recent scale-up, however, most reports on resistance have been preliminary, involving small cohorts of drug-exposed subjects benefiting from free ARV supplies.